Journal Article10.1164/AJRCCM.155.4.9105068
Quality of life changes in COPD patients treated with salmeterol.
Paul W. Jones,Teresa K. Bosh +1 more
527
TL;DR: It is shown that a modest change in lung function may be associated with clinically significant gain in health and well-being in COPD patients.
read more
Abstract: Changes in health-related quality of life (HRQoL) were evaluated in patients with chronic obstructive pulmonary disease (COPD) following treatment with placebo, salmeterol 50 microg twice a day or 100 microg twice a day by metered-dose inhaler Patients completed the disease-specific St George's Respiratory Questionnaire (SGRQ) and the Medical Outcomes Study Short Form 36 (SF-36) at baseline and after 16 wk of treatment Data from 283 patients (95 patients in the placebo group and 94 in each salmeterol group) were available for HRQoL analysis Apart from a small difference in ages, all treatment groups were well matched at baseline in terms of forced expiratory volume in one second (FEV1) and HRQoL scores Compared with placebo, salmeterol 50 microg twice a day was associated with significant improvements in SGRQ "Total" and "Impacts" scores which exceeded the threshold for a clinically significant change This was not seen with salmeterol 100 microg twice a day Changes in SGRQ and SF-36 scores correlated They also showed a weak but significant relationship with FEV1 This study has shown that a modest change in lung function may be associated with clinically significant gain in health and well-being in COPD patients
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.
Jørgen Vestbo,Suzanne S. Hurd,Alvar Agusti,Paul W. Jones,Claus Vogelmeier,Antonio Anzueto,Peter J. Barnes,Leonardo M. Fabbri,Fernando J. Martinez,Masaharu Nishimura,Robert A. Stockley,Don D. Sin,Roberto Rodriguez-Roisin +12 more
TL;DR: It is recommended that spirometry is required for the clinical diagnosis of COPD to avoid misdiagnosis and to ensure proper evaluation of severity of airflow limitation.
18.2K
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.
TL;DR: List of participants (GOLD Scientific Committee): Nicholas Anthonisen, Winnipeg, Canada, William C. Bailey, Birmingham, US, Tim Clark, London, UK, Leonardo Fabbri, Modena, Italy, Yoshinosuke Fukuchi, Tokyo, Japan; Lawrence Grouse, Seattle, US; James C. Hogg, Vancouver, Canada; Dirkje S. Postma, Groningen, the Netherlands.
6.8K
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
Bartolome R. Celli,William MacNee,Alvar Agusti,Antonio Anzueto,B. Berg,A. S. Buist,Peter M.A. Calverley,Niels H. Chavannes,T. Dillard,Bonnie F. Fahy,Alan M. Fein,John E. Heffner,Suzanne C. Lareau,Paula Meek,Fernando J. Martinez,Walter T. McNicholas,Jean W M Muris,E. Austegard,Romain Pauwels,S. I. Rennard,Adriano G. Rossi,NM Siafakas,B. Tiep,Jørgen Vestbo,E. F. M. Wouters,Richard ZuWallack +25 more
TL;DR: The main goals of the updated document are to improve the quality of care provided to patients with COPD and to develop the project using a disease-oriented approach.
4.7K
Interpretation of changes in health-related quality of life the remarkable universality of half a standard deviation
TL;DR: In most circumstances, the threshold of discrimination for changes in health-related quality of life for chronic diseases appears to be approximately half a SD, which research in psychology has shown is approximately 1 part in 7.
4.5K
Global initiative for chronic obstructive lung disease.
Lynn B. Gerald,William C. Bailey +1 more
TL;DR: Representatives from many countries serve as a network for the dissemination and implementation of programs for diagnosis, management, and prevention of COPD.
3.8K
References
Measurement of health status: Ascertaining the minimal clinically important difference
TL;DR: An approach to elucidating the significance of changes in score in quality of life instruments by comparing them to global ratings of change is developed, and a plausible range within which the minimal clinically important difference (MCID) falls is established.
4.8K
A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire.
TL;DR: The St. George's Respiratory Questionnaire is a valid measure of impaired health in diseases of chronic airflow limitation that is repeatable and sensitive andMultivariate analysis demonstrated that SGRQ scores summed a number of areas of disease activity.
3.1K
The St George's Respiratory Questionnaire.
TL;DR: The St George's Respiratory Questionnaire is a standardized self-completed questionnaire for measuring impaired health and perceived well-being in airways disease and the background and rationale for its development are discussed together with an analysis of its performance.
2.9K
A measure of quality of life for clinical trials in chronic lung disease.
TL;DR: It has been shown that the questionnaire is precise, valid, and responsive and can therefore serve as a useful disease specific measure of quality of life for clinical trials.
•Journal Article
A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group.
TL;DR: There was a lower incidence of asthma and related events during salmeterol treatment compared to salbutamol treatment subgroups, and the diurnal variation in PEFR, nocturnal and daytime symptoms and use of additional sal butamol were significantly lower in the sal meterol treated group.
181